Table 3.
Univariate and Multivariate Analysis of Predictors of Overall Survival
| Factor | No. of Patients | 5-Year Overall Survival (%) | Median Overall Survival (months) | Univariate Analysis |
Multivariate Analysis |
||||
|---|---|---|---|---|---|---|---|---|---|
| P | HR | 95% CI | P | HR | 95% CI | ||||
| Age, years | |||||||||
| > 60 | 80 | 49.7 | 51.2 | .528 | 1.15 | 0.74 to 1.75 | |||
| ≤ 60 | 129 | 54.3 | 84.7 | ||||||
| Primary tumor nodal status | |||||||||
| Positive | 126 | 44.6 | 49.0 | .003 | 2.01 | 1.27 to 3.28 | .009 | 2.04 | 1.25 to 3.46 |
| Negative | 76 | 65.1 | 114.2 | ||||||
| Extrahepatic disease | |||||||||
| Present | 17 | 49.3 | 30.1 | .196 | 1.68 | 0.74 to 3.27 | |||
| Absent | 192 | 53.2 | 84.7 | ||||||
| Adjuvant chemotherapy for primary tumor within 1 year of diagnosis of CLM | |||||||||
| Yes | 18 | 37.3 | 35.4 | .079 | 1.97 | 0.92 to 3.73 | .529 | ||
| No | 191 | 53.8 | 84.7 | ||||||
| DFI, years | |||||||||
| < 1 | 151 | 50.7 | 60.1 | .556 | 1.15 | 0.73 to 1.89 | |||
| ≥ 1 | 58 | 56.1 | 90.3 | ||||||
| Preoperative chemotherapy regimen | |||||||||
| Oxaliplatin | 140 | 52.6 | 90.3 | .896 | 0.97 | 0.63 to 1.52 | |||
| Irinotecan | 69 | 51.5 | 60.1 | ||||||
| Bevacizumab | |||||||||
| No | 101 | 48.2 | 54.3 | .232 | 1.31 | 0.84 to 2.05 | |||
| Yes | 108 | 59.9 | NA | ||||||
| No. of tumors | |||||||||
| Multiple | 131 | 37.9 | 58.1 | .208 | 1.32 | 0.86 to 2.07 | |||
| Solitary | 78 | 58.4 | 90.3 | ||||||
| Size of largest metastasis before surgery, cm | |||||||||
| > 5 | 38 | 41.1 | 44.3 | .116 | 1.51 | 0.89 to 2.44 | |||
| ≤ 5 | 171 | 55.6 | 88.3 | ||||||
| Surgical margin | |||||||||
| Positive | 17 | 19.2 | 44.0 | .060 | 1.93 | 0.97 to 3.49 | .032 | 2.21 | 1.08 to 4.14 |
| Negative | 189 | 55.8 | 88.3 | ||||||
| Adjuvant chemotherapy | |||||||||
| No | 49 | 38.3 | 44.3 | .035 | 1.65 | 1.04 to 2.54 | .060 | ||
| Yes | 160 | 57.1 | 90.3 | ||||||
| RECIST response | |||||||||
| SD or PD | 140 | 47.7 | 51.0 | .055 | 1.57 | 0.99 to 2.58 | .148 | ||
| PR | 69 | 61.7 | 88.3 | ||||||
| Morphologic response | |||||||||
| Suboptimal | 146 | 43.7 | 49.0 | < .001 | 2.48 | 1.46 to 4.49 | .007 | 2.09 | 1.22 to 3.83 |
| Optimal | 63 | 73.8 | 114.2 | ||||||
Abbreviations: CLM, colorectal liver metastases; DFI, disease-free interval from diagnosis of primary tumor to diagnosis of liver metastases; HR, hazard ratio; NA, not available; PD, progressive disease; PR, partial response; SD, stable disease.